Cargando…
Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
ErbB2 is an important member of the ErbB family, which activates growth and proliferation signaling pathways. ErbB2 is often overexpressed in various malignancies, especially in breast cancer, and is a common target for anti-cancer drugs. Breast cancer is currently one of the leading mortality cause...
Autores principales: | Wolfson, Eya, Goldenberg, Maria, Solomon, Shira, Frishberg, Amit, Pinkas-Kramarski, Ronit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323158/ https://www.ncbi.nlm.nih.gov/pubmed/27542246 http://dx.doi.org/10.18632/oncotarget.11323 |
Ejemplares similares
-
Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018) -
Identification of Nucleolin as New ErbB Receptors- Interacting Protein
por: Di Segni, Ayelet, et al.
Publicado: (2008) -
Structure-Function Analysis of Nucleolin and ErbB Receptors Interactions
por: Farin, Keren, et al.
Publicado: (2009) -
Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma
por: Goldshmit, Yona, et al.
Publicado: (2014) -
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)